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BACKGROUND. Laboratory studies suggest that flavonoids are antimutagenic and
anticarcinogenic. To investigate the associations between commonly consumed
flavonoid compounds and lung cancer, the authors conducted a population-
based case–control study of 558 lung cancer cases and a group of 837 controls.
METHODS. Dietary intakes of flavonoids were estimated by combining the intake
frequency (collected by a food frequency questionnaire), portion size, and food
composition data. Unconditional logistic regression analysis was used to estimate
odds ratios (ORs) and 95% confidence limits (95% CLs) with an adjustment for
potential confounders, including age, sex, race-ethnicity, years of schooling,
smoking status, pack-years of tobacco smoking, and daily energy intake.
RESULTS. Lung cancer was associated inversely with the consumption of epicate-
chin (in 10 mg per day increment: OR, 0.64; 95% CL, 0.46–0.88), catechin (4 mg
per day increment: OR, 0.49; 95% CL, 0.35–0.70), quercetin (9 mg per day incre-
ment: OR, 0.65; 95% CL, 0.44–0.95), and kaempferol (2 mg per day increment:
OR, 0.68; 95% CL, 0.51–0.90) among tobacco smokers. There was little association
between lung cancer and the flavonoid compounds mentioned above among
nonsmokers. Regardless of smoking status, there was little association with total
flavonoids: thearubigins, hesperetin, naringenin, and myricetin. In addition, con-
sumption of vegetables, tea, and wine, all of which are rich sources of flavonoids,
was associated inversely with lung cancer among tobacco smokers.
CONCLUSIONS. Certain flavonoid compounds, including epicatechin, catechin,
quercetin, and kaempferol, were associated inversely with lung cancer among
tobacco smokers, but not among nonsmokers. Further studies of these as-
sociations may be warranted. Cancer 2008;112:2241–8.  2008 American Cancer
Society.
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E pidemiologic studies have identified inverse associationsbetween the consumption of fruits and vegetables and various
cancers.1,2 Plant-derived foods contain a wide variety of antioxi-
dants, such as phytochemicals, and vitamins that scavenge reactive
oxygen species (ROS) and may interact to prevent cancers. Consid-
erable attention has been paid to vitamins C and E and carotenoids
from fruits and vegetables because of their antioxidant properties.
However, to date, large randomized trials have not demonstrated
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the expected protective effects of these micronutri-
ents,3,4 suggesting that other plant compounds may
be responsible for the epidemiologic observations.
Laboratory studies indicate that other phytochem-
icals are major contributors to the antioxidant activity
of fruits and vegetables, and a strong, positive correla-
tion has been observed between the antioxidant activ-
ity and total content of polyphenols, which are the
major components of phytochemicals.5,6
Polyphenols comprise flavonoids, phenolic acids,
stilbenes, and lignans.7 Flavonoids are the most
widely distributed and account for approximately
two-thirds of plant polyphenols in the human diet.
Cao et al. observed that some flavonoids have much
stronger antioxidant activities against peroxyl radicals
than vitamins C and E and glutathione.8 It has been
estimated that the average daily intake of flavonoids
in the United States population is between 20 mg
and 1 g.9 Although storage conditions may influence
their levels, flavonoids are heat stable and are subject
to relatively low loss during cooking and frying.10
Furthermore, dietary ingredient interactions may have
little influence on the bioavailability of flavonoids.9
Several flavonoids exhibit anticancer activity in
various in vitro and in vivo models.11 Various
mechanisms for these effects have been proposed
and supported by laboratory experiments, includ-
ing antioxidation, induction of detoxification en-
zymes and inhibition of bioactivation enzymes,
estrogenic and antiestrogenic activity, antiprolifera-
tion, cell cycle arrest and apoptosis, promotion of
differentiation, regulation of host-immune function,
and inhibition of angiogenesis.9,11 However, the
aforementioned laboratory experimental studies have
largely have involved concentrations that are much
higher than those in human diets.12 Thus, there is a
need for epidemiologic studies of natural human
intake levels. Herein, we report a population-based
case–control study in Los Angeles County in which
we evaluated dietary flavonoid compounds in asso-
ciation with lung cancer.
MATERIALS AND METHODS
Study Design and Subject Selection
Study design, recruitment, and data collection have
been described in detail elsewhere.13 In brief, we
conducted a population-based case–control study in
Los Angeles County during the period from 1999 to
2004. The study involved 611 newly diagnosed cases
of lung cancer, 601 newly diagnosed cases of upper
aerodigestive tract cancers, and a group of 1040
cancer-free controls. Histologically confirmed cases
were obtained by using the rapid ascertainment sys-
tem of the Cancer Surveillance Program for Los
Angeles County. Controls with no history of investi-
gated cancers were recruited from the neighborhood
of the cases. Cases and controls were matched by
age (within 10-year categories) and sex. Participants
were residents of Los Angeles County at the time of
diagnosis for cases or at study entry for controls.
Participants ranged in age from 18 years to 65 years
during the enrollment period, and spoke English, or
Spanish, or had translators available at home. In-per-
son interviews were conducted by using standardized
questionnaires to collect information on sociodemo-
graphic characteristics, history of tobacco smoking,
environmental tobacco smoking, drug and alcohol use,
occupational and environmental exposures, selected
clinical factors, dietary history, family history of cancer,
and other potential risk or protective factors associated
with lung and head and neck cancers.
The current study focuses on lung cancer only.
We excluded participants who had no food frequency
questionnaire (FFQ) data (44 lung cancer cases and
183 controls) or who had an energy intake <500 cal-
ories per day or >4500 calories per day (9 lung can-
cer cases and 12 controls). We also excluded 8
controls from the study because they were >3 years
younger than the youngest case or 3 years older than
the oldest case. This left 558 lung cancer cases and
837 controls. The Institutional Review Boards of the
University of California at Los Angeles and the Uni-
versity of Southern California approved the research
protocol. Informed consent was obtained from all
study participants.
Nutrient Intake Assessment
The semiquantitative FFQ that was used in this study
was based on the validated ‘‘Brief Block FFQ’’
(National Cancer Institute), which has been validated
for estimating essential nutrients.14 To enhance our
ability to estimate micronutrients and phytochem-
icals, we included more vegetable and fruit items in
the questionnaire. The reference period of the dietary
intake was 1 year before diagnosis for cases and
1 year before interview for controls. For seasonal foods,
the reference period was limited to the period during
which each food was available. Frequencies con-
sumed were sought for 78 food items, including tea,
wine, and commonly consumed vegetables (beans,
tofu/soy beans, raw tomatoes, cooked tomatoes/
tomato sauce, salsa/picante/taco sauce, broccoli,
spinach, mustard greens/turnip greens/collards, cole
slaw/cabbage, carrots, winter squash, green salad,
and sweet potatoes/yams) and fruits (apples/pears,
cantaloupe, watermelon, oranges, orange juice/grape
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juice, grapefruit, peaches/nectarines/apricots/plums,
bananas, strawberries, and other fruit juices).
The daily nutrient intake from a given food was
calculated by multiplying its portion size (in grams)
by the number of servings per day and its nutrient
contents. Then, the daily nutrient intake for each
study participant was calculated by summing across
all food items. The portion sizes of food items from
the original Brief Block FFQ and of the added items
were obtained from Dietsys (version 4.02; avail-
able from: http://appliedresearch.cancer.gov/DietSys/
materials.html; accessed on February 26, 2008) and
the U.S. Department of Agriculture (USDA) portion
size database, respectively. Food composition data
from Dietsys were applied to estimate the intake of
macronutrients, vitamins, and minerals. The compo-
sition data from the USDA were used to estimate the
intake of flavonoids (available from: http://www.
nal.usda.gov/fnic/foodcomp/Data/Flav/flav.html; ac-
cessed on February 26, 2008). A seasonality factor
was used to adjust the intake frequencies of seasonal
foods. For any food item composed of multiple
foods, a given nutrient content was calculated as the
weighted mean content of those combined multiple
foods. The mean intake for each food, estimated
from the Continuing Survey of Food Intakes by Indi-
viduals, 1994–1996, was used as its weight.
Statistical Analysis
We used unconditional logistic regression analysis
that included matching factors as indicators, which
allowed us to include cases with no matched con-
trols and all available controls that met the inclusion
criteria. Odds ratios (ORs) and 95% confidence limits
(95% CLs) were calculated with an adjustment for
potential confounders, including age, sex, race/ethni-
city (non-Hispanic white, black, Hispanic, other),
educational level (years of schooling), tobacco smok-
ing (pack-years and status), and daily energy intake
(calories). To minimize age confounding, age was
controlled in fine categories (ages 29–34 years, 35–
36 years, 37–38 years, 39–40 years, 41–42 years, 43–44
years, 45–46 years, 47–48 years, 49–50 years, 51–
52 years, 53–54 years, 55–56 years, 57–58 years, and
59–62 years). Dietary intakes of nutrients were
adjusted for total energy intake by using the residual
method described by Willett et al.15 These nutrients
were analyzed either as continuous variables (with
rescaling and exclusion of outliers to avoid the lever-
age) or as categorical variables. The rescaling units
for the continuous analyses were chosen to fall
within the span of the data and to correspond to fea-
sible intervention ranges. All data analyses were per-
formed in SAS version 8.2 (SAS Institute, Cary, NC),
and all P values were 2-sided.
RESULTS
Distributions of selected demographic and potential
confounding factors by disease status are summar-
ized in Table 1. Compared with the control group,
the case group had a similar age but lower propor-
tions of men, whites, and Hispanics. Overall, cases
consumed more tobacco and calories and they had
less educational background than controls.
The median intake of total flavonoids among
controls was approximately 60 mg per day, and the
intake amount varied considerably (interquartile
range, 75 mg per day). Flavan-3-ols (median, 15 mg
per day; interquartile range, 40 mg per day), flava-
nones (median, 22 mg per day; interquartile range,
35 mg per day), and flavonols (median, 6 mg per
day; interquartile range, 5 mg per day) were main
contributors to flavonoid intake in this population;
whereas isoflavonoids (median, 60 lg per day; inter-
quartile range, 1306 lg per day), flavones (median,
19 lg per day; interquartile range, 62 lg per day),
and anthocyanidins (median, 0.9 lg per day; inter-
quartile range, 387 lg per day) only contributed to a
TABLE 1





cases, n 5 558
Controls,
n 5 837
Mean  SD age, y 52  5 50  7
Sex
Women 274 (49.1) 339 (40.5)
Men 284 (50.9) 498 (59.5)
Race-ethnicity
Non-Hispanic white 332 (59.5) 530 (63.3)
Black 86 (15.4) 83 (9.9)
Hispanic 61 (10.9) 146 (17.5)
Other 79 (14.2) 78 (9.3)
Mean  SD schooling, y 13  3 14  4
Smoking status
Never 96 (17.2) 390 (46.6)
Ever 462 (82.8) 447 (53.4)
Median pack-years for
ever-smokers
[interquartile range] 35 [26] 12 [27]
Mean  SD daily
energy intake, calories 1529  667 1480  597
SD indicates standard deviation.
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trace amount of flavonoids. Thearubigins (median,
4 mg per day; interquartile range, 24 mg per day),
epicatechin (median, 5 mg per day; interquartile
range, 7 mg per day), and catechin (median, 2 mg
per day; interquartile range, 2 mg per day) were the
commonly consumed flavan-3-ols; hesperetin (me-
dian, 14 mg per day; interquartile range, 22 mg per
day) and naringenin (median, 6 mg per day; inter-
quartile range, 13 mg per day) were the commonly
consumed flavanones; and quercetin (median, 5 mg
per day; interquartile range, 4 mg per day), kaemp-
ferol (median, 734 lg per day; interquartile range,
1070 lg per day), and myricetin (median, 405 lg per
day; interquartile range, 692 lg per day) were the
commonly consumed flavonols.
Table 2 shows the distribution of total flavonoid
intake stratified on selected characteristics among
controls. Only small differences in total flavonoid
intake were detected among different groups defined
separately by age, education, and daily energy intake.
In contrast, women and nonsmokers or light smokers
ingested more flavonoids than men and heavy smo-
kers (>20 pack-years), respectively. In addition,
blacks consumed less flavonoids than other groups.
The adjusted associations between dietary in-
takes of total flavonoids and commonly consumed
flavonoid compounds and lung cancer are summar-
ized in Table 3. We detected little association
between lung cancer and total flavonoids, thearubi-
gins, naringenin, and myricetin. In contrast, lung
cancer was associated inversely with the consump-
tion of epicatechin (10 mg per day increment: OR,
0.64; 95% CL, 0.46–0.88; P value for trend
[Ptrend] 5 .0066), catechin (4 mg per day increment:
OR, 0.49; 95% CL, 0.35–0.70; Ptrend < .0001), querce-
tin (9 mg per day increment: OR, 0.65; 95% CL, 0.44–
0.95; Ptrend 5 .0025), and kaempferol (2 mg per day
increment: OR, 0.68; 95% CL, 0.51–0.90;
Ptrend 5 .0079) among tobacco smokers. Nonetheless,
there was little association between lung cancer and
epicatechin, catechin, quercetin, and kaempferol
among nonsmokers. In addition, there was some evi-
dence of hesperetin associated positively with lung
cancer (30 mg per day vs <10 mg per day; OR, 1.6;
95% CL, 1.0–2.4) among tobacco smokers in categori-
cal analysis, although little association was observed
in continuous analysis.
Vegetables, fruits, tea, and wine are rich sources
of epicatechin, catechin, quercetin, and kaempferol.
We observed an inverse association of lung cancer
with vegetables (3 servings per day increment: OR,
0.59; 95% CL, 0.42–0.83; Ptrend 5 .0026) and tea (1
cup per day increment: OR, 0.79; 95% CL, 0.63–0.98;
Ptrend 5 .033) consumed in the past year among
tobacco smokers (Table 4). Nonetheless, little asso-
ciation was observed among nonsmokers. Similarly,
wine intake in the past year was associated inversely
with lung cancer among smokers (1 glass per day in-
crement: OR, 0.76; 95% CL, 0.59, 0.97; Ptrend 5 .029);
Among nonsmokers, there were too few data to
make a determination. When assessing life-time wine
drinking history, the inverse association among smo-
kers was detected only among those who drank
moderately (no more than 1 glass per day). Further
investigation on the association between wine intake
and lung cancer risk is warranted given the see-
mingly inconsistent results. In addition, total fruit
intake was not associated with lung cancer, regard-
less of smoking status.
DISCUSSION
Consistent with our findings, in 1 hospital-based
case–control study, an inverse association was
observed between black tea consumption and lung
cancer (OR, 0.34; 95% CL, 0.14, 0.84) among smoking
men.16 An anticarcinogenic effect of tea consumption
may arise through scavenging of ROS, inhibition of
TABLE 2
Distribution of Total Flavonoid Intake Stratified on Selected
Characteristics Among Controls
Key variable
No. (%) of controls within categories of
total flavonoid intake
<30 mg/d 30–<60 mg/d 60–<90 mg/d >90 mg/d
Age, y
17–44 43 (25) 47 (27) 27 (16) 55 (32)
45–54 105 (26) 106 (26) 75 (18) 120 (30)
>54 60 (23) 55 (21) 47 (18) 97 (38)
Sex
Men 134 (27) 135 (27) 84 (17) 145 (29)
Women 74 (22) 73 (22) 65 (19) 127 (37)
Race-ethnicity
White 140 (26) 132 (25) 90 (17) 168 (32)
Black 27 (32) 19 (23) 14 (17) 23 (28)
Hispanic 27 (19) 37 (25) 34 (23) 48 (33)
Other 14 (17) 20 (26) 11 (14) 33 (43)
Education, y
0–12 58 (24) 57 (24) 44 (19) 79 (33)
13–16 101 (26) 101 (26) 77 (20) 112 (28)
>16 49 (24) 50 (24) 28 (13) 81 (39)
Pack-years of tobacco smoking
Never 85 (22) 97 (25) 84 (21) 124 (32)
1–20 72 (25) 63 (22) 46 (16) 107 (37)
>20 51 (32) 48 (30) 19 (12) 41 (26)
Daily energy intake, calories
<1000 51 (30) 47 (28) 31 (18) 41 (24)
1000–2000 124 (23) 125 (24) 89 (17) 188 (36)
>2000 33 (23) 36 (26) 29 (21) 43 (30)
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TABLE 3
Associations of Total Flavonoids and Commonly Consumed Flavonoid Compounds With Lung Cancer Risk
Compound
All study participants Smokers Nonsmokers
No. (%) No. (%) No. (%)
Cases Controls OR [95% CL]* Cases Controls OR [(95% CL]* Cases Controls OR [95% CL]y
Total flavonoids
200 mg/d{ 558 (100) 837 (100) 1.1 [0.84–1.4] 462 (100) 447 (100) 0.93 [0. 69–1.3] 96 (100) 390 (100) 1.3 [0.86–1.9]
Ptrend .53 .63 .23
<30 mg/d 174 (31) 209 (25) 1.0 160 (35) 124 (28) 1.0 14 (15) 85 (22) 1.0
30–<60 mg/d 130 (23) 206 (25) 0.98 [0.68–1.4] 109 (24) 112 (25) 0.94 [0.62–1.4] 21 (22) 94 (24) 1.2 [0.53–2.6]
60–<90 mg/d 73 (13) 137 (16) 0.87 [0.57–1.3] 61 (13) 60 (13) 0.98 [0.59–1.6] 12 (12) 77 (20) 0.70 [0.29–1.7]
9 mg/d 181 (33) 285 (34) 1.1 [0.80–1.6] 132 (28) 151 (34) 0.97 [0.65–1.5] 49 (51) 134 (34) 1.4 [0.68–2.8]
Thearubigins
40 mg/d{ 539 (97) 819 (98) 0.85 [0.72–1.0] 445 (96) 437 (98) 0.81 [0.65–1.0] 94 (98) 382 (98) 0.93 [0.68–1.3]
Ptrend .081 .062 .63
<5 mg/d 325 (58) 460 (55) 1.0 276 (60) 241 (54) 1.0 49 (51) 219 (56) 1.0
5–<25 mg/d 103 (19) 166 (20) 0.90 [0.64–1.3] 81 (17) 83 (19) 0.83 [0.54–1.3] 22 (23) 83 (21) 1.2 [0.65–2.3]
25 mg/d 130 (23) 211 (25) 0.86 [0.63–1.2] 105 (23) 123 (27) 0.77 [0.53–1.1] 25 (26) 88 (23) 1.1 [0.59–2.0]
Epicatechin
10 mg/d{ 558 (100) 837 (100) 0.69 [0.53–0.91] 462 (100) 447 (100) 0.64 [0.46–0.88] 96 (100) 390 (100) 0.85 [0.53–1.4]
Ptrend .0073 .0066 .52
<3 mg/d 242 (44) 270 (32) 1.0 210 (46) 145 (32) 1.0 32 (33) 125 (32) 1.0
3–<6 mg/d 129 (23) 250 (25) 0.88 [0.63–1.2] 102 (22) 106 (24) 0.82 [0.54–1.2] 27 (28) 99 (25) 1.1 [0.56–2.0]
6–<9 mg/d 80 (14) 154 (18) 0.67 [0.45–0.99] 62 (13) 87 (20) 0.55 [0.34–0.89] 18 (19) 67 (18) 1.1 [0.52–2.3]
9 mg/d 107 (19) 208 (25) 0.66 [0.46–0.94] 88 (19) 109 (24) 0.61 [0.40–0.93] 19 (20) 99 (25) 0.81 [0.40–1.6]
Catechin
4 mg/d{ 548 (98) 820 (98) 0.56 [0.41–0.76] 454 (98) 437 (98) 0.49 [0.35–0.70] 94 (98) 383 (98) 0.77 [0.41–1.4]
Ptrend .0002 <.0001 .41
<1 mg/d 216 (39) 202 (24) 1.0 189 (41) 104 (23) 1.0 27 (28) 98 (25) 1.0
1–<2 mg/d 130 (23) 185 (22) 0.77 [0.54–1.1] 100 (22) 100 (23) 0.67 [0.43–1.0] 30 (31) 85 (22) 1.1 [0.54–2.1)
2–<3 mg/d 72 (13) 172 (21) 0.38 [0.25–0.57] 58 (12) 86 (19) 0.33 [0.20–0.55] 14 (15) 86 (22) 0.44 [0.20–0.97]
3 mg/d 140 (25) 278 (33) 0.54 [0.38–0.76] 115 (25) 157 (35) 0.44 [0.29–0.66] 25 (26) 121 (31) 0.77 [0.39–1.5]
Hesperetin
80 mg/d{ 549 (98) 826 (99) 1.7 [1.0–2.9] 456 (99) 441 (99) 1.7 [0.88–3.3] 93 (97) 385 (99) 1.5 [0.61–3.8]
Ptrend .044 .11 .37
<10 mg/d 256 (46) 341 (41) 1.0 236 (51) 212 (48) 1.0 20 (21) 129 (33) 1.0
10–<20 mg/d 92 (16) 170 (20) 1.1 [0.77–1.6] 74 (16) 86 (19) 1.1 [0.71–1.7] 18 (19) 84 (22) 1.5 [0.69–3.1]
20–<30 mg/d 76 (14) 123 (15) 1.2 [0.82–1.8] 59 (13) 63 (14) 1.2 [0.73–1.9] 17 (18) 60 (15) 1.6 [0.75–3.6]
30 mg/d 134 (24) 203 (24) 1.6 [1.1–2.2] 93 (20) 86 (19) 1.6 [1.0–2.4] 41 (42) 117 (30) 1.7 [0.88–3.3]
Naringenin
30 mg/d{ 546 (98) 825 (99) 1.2 [0.92–1.6] 453 (98) 440 (98) 1.3 [0.87–1.8] 93 (97) 385 (99) 1.1 [0.71–1.7]
Ptrend .17 .22 .65
<5 mg/d 273 (49) 370 (44) 1.0 244 (53) 227 (51) 1.0 29 (30) 143 (36) 1.0
5–<10 mg/d 111 (20) 184 (22) 1.2 [0.82–1.7] 92 (20) 91 (20) 1.3 [0.84–1.9] 19 (20) 93 (24) 1.0 [0.53–2.1]
10–<15 mg/d 57 (10) 78 (9) 1.8 [1.2–2.9] 43 (9) 32 (7) 2.2 [1.2–3.9] 14 (15) 46 (12) 1.4 [0.60–3.1]
15 mg/d 117 (21) 205 (25) 1.3 [0.95–1.9] 83 (18) 97 (22) 1.4 [0.90–2.1] 34 (35) 108 (28) 1.1 [0.61–2.1]
Quercetin
9 mg/d{ 558 (100) 837 (100) 0.77 [0.56–1.1] 462 (100) 447 (100) 0.65 [0.44–0.95] 96 (100) 390 (100) 1.1 [0.64–1.9]
Ptrend .11 .025 .72
<2.5 mg/d 151 (27) 148 (18) 1.0 137 (30) 88 (20) 1.0 14 (15) 60 (16) 1.0
2.5–<5 mg/d 206 (37) 286 (34) 0.92 [0.65–1.3] 175 (38) 148 (33) 0.92 [0.61–1.4] 31 (32) 138 (35) 1.1 [0.50–2.4]
5–<7.5 mg/d 99 (18) 208 (25) 0.66 [0.44–0.98] 71 (15) 102 (23) 0.54 [0.33–0.87] 28 (29) 106 (27) 1.1 [0.48–2.5]
7.5 mg/d 102 (18) 195 (23) 0.71 [0.47–1.1] 79 (17) 109 (24) 0.63 [0.39–1.0] 23 (24) 86 (22) 0.98 [0.43–2.3]
Kaempferol
2 mg/d{ 551 (99) 837 (100) 0.72 [0.56–0.91] 457 (99) 447 (100) 0.68 [0.51–0.90] 94 (98) 390 (100) 0.76 [0.48–1.2]
Ptrend .0069 .0079 .25
<0.5 mg/d 246 (44) 303 (36) 1.0 215 (47) 162 (36) 1.0 31 (32) 141 (36) 1.0
0.5–<1 mg/d 141 (25) 217 (26) 0.97 [0.70–1.3] 120 (26) 111 (25) 0.98 [0.67–1.4] 21 (22) 106 (27) 0.97 [0.49–1.9]
1–<1.5 mg/d 70 (13) 133 (16) 0.73 [0.49–1.1] 53 (11) 75 (17) 0.59 [0.36–0.96] 17 (18) 58 (15) 1.1 [0.55–2.4]
(continued )
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angiogenesis, and induction of apoptosis and
enzymes involved in carcinogen detoxification.17,18
Both green tea and black tea extracts can inhibit
lung tumorigenesis induced by tobacco-specific
nitrosamine and benzo(a)pyrene in animals.18–20
Catechins appear to have antimutagenic and anticar-
cinogenic activities against a wide variety of muta-
gens, including benzo(a)pyrene and aflatoxin B1, and
their activities are several times more powerful than
those of vitamin C.17 Nonetheless, previous epide-
miologic studies of the association of lung cancer
with tea consumption and intake of catechins have
been inconsistent, with most of those studies report-
ing no associations.21–24
Experimental studies have demonstrated that
quercetin inhibits carcinogenesis in human lung can-
cer cells in vitro and inhibits N-nitrosodiethylamine-
induced lung tumorigenesis in animal models.25
Quercetin exerts its anticancer effect through multi-
ple pathways, including scavenging of ROS, inhibi-
tion of carcinogen bioactivation enzymes, induction
of carcinogen-conjugating enzymes, and induction of
cell cycle arrest and apoptosis.26–28 We observed an
inverse association between quercetin intake and
lung cancer, suggesting its protective effect. The
inverse association was consistent with some previ-
ous studies. One cohort study observed an inverse
association of quercetin and lung cancer (risk ratio
[RR], 0.42; 95% CL, 0.25–0.72).29 Similarly, a popula-
tion-based case–control study in Hawaii observed an
inverse association of lung cancer with the main
source of quercetin: onions (OR, 0.5; 95% CL, 0.3–
0.9) and apples (OR, 0.6; 95% CL–0.4, 1.0).21 By using
baseline data collected in the Alpha-Tocopherol,
Beta-Carotene Cancer Prevention study, an inverse
association (RR, 0.56; 95% CL, 0.45–0.69) between fla-
vonol and flavone intake and lung cancer was
observed among male smokers.30 In that study,
>85% of the intake of flavonols and flavones was
ascribed to quercetin.
Two epidemiologic studies reported little associa-
tion between the dietary intake of kaempferol,
another rich flavonol compound, and lung can-
cer.21,29 In contrast, we observed that kaempferol
was associated inversely with lung cancer. Kaemp-
ferol, which is structurally similar to quercetin, may
be an important chemopreventive agent, because of
the findings that 1) it is a potent scavenger of super-
oxide anion and peroxynitrite, thereby blocking oxi-
dative stress31; 2) it can inhibit the activity of several
enzymes involved in cell growth and signal transduc-
tion pathways including cyclic AMP phosphodiester-
ase32; and 3) it inhibits cell growth and induces
apoptosis in A549 lung cancer cells.33
Some flavonoid compounds that were investi-
gated in the current study were not associated with
lung cancer. The estimated effect differences among
various flavonoid compounds may have been caused
by chance or by differences in their chemical struc-
ture, bioavailability, distribution, and metabolism.34
In vitro studies have indicated considerable differ-
ences in the antioxidative potential of different flavo-
noid compounds.34 It was striking that the inverse




All study participants Smokers Nonsmokers
No. (%) No. (%) No. (%)
Cases Controls OR [95% CL]* Cases Controls OR [(95% CL]* Cases Controls OR [95% CL]y
1.5 mg/d 101 (18) 184 (22) 0.77 [0.54–1.1] 74 (16) 99 (22) 0.66 [0.42–1.0] 27 (28) 85 (22) 1.1 [0.55–2.0]
Myricetin
1 mg/d{ 538 (96) 811 (97) 0.86 [0.70–1.1] 445 (96) 429 (96) 0.83 [0.62–1.1] 93 (97) 382 (98) 0.86 [0.55–1.3]
Ptrend .21 .22 .52
<200 lg/d 148 (26) 219 (26) 1.0 110 (24) 94 (21) 1.0 38 (40) 125 (32) 1.0
200–<400 lg/d 112 (20) 182 (22) 0.68 [0.46–1.0] 95 (21) 90 (20) 0.70 [0.44–1.1] 17 (18) 92 (24) 0.64 [0.32–1.3]
400–<600 lg/d 77 (14) 131 (16) 0.71 [0.46–1.1] 70 (15) 78 (18) 0.71 [0.43–1.2] 7 (7) 53 (13) 0.52 [0.20–1.3]
600 lg/d 221 (40) 305 (36) 0.77 [0.55–1.1] 187 (40) 185 (41) 0.68 [0.45–1.0] 34 (35) 120 (31) 0.94 [0.51–1.7]
OR indicates odds ratio; 95% CL, 95% confidence limits.
*Adjusted for age (in 14 fine categories), sex, race-ethnicity (non-Hispanic white, black, Hispanic, other), years of schooling, smoking status (ever vs never), pack-years of tobacco smoking, and daily energy
intake.
yAdjusted for age (in 14 fine categories), sex, race-ethnicity (non-Hispanic white, black, Hispanic, other), years of schooling, and daily energy intake.
{ Treating intakes of flavonoid compounds as continuous variables with rescaling and exclusion of outliers.
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tin, kaempferol, and lung cancer were present only
among smokers. Those results may reflect the finding
that these flavonoid compounds are strong antioxi-
dants against ROS generated by tobacco smoking.
This interpretation also is supported by the finding
that these compounds can inhibit tobacco-specific,
carcinogen-induced lung tumorigenesis in animal
models.11
Among the strengths of the current study are
its population-based study design, relatively large
sample size, and comprehensive questionnaire data.
Nonetheless, there are several limitations. Measure-
ment error must be considerable because of retro-
spective data collection and intrinsic limitations of
the FFQ. The reference period of our FFQ is 1 year
before diagnosis for cases and 1 year before interview
for controls. Therefore, the collected intake data may
not reflect relevant exposures (dietary intakes of
more than a few years ago) considering the long la-
tency of lung cancer. Previous studies have demon-
strated that individuals tend to over-report their
intake of fruits and vegetables.35 Bias would occur if
there was differential misreporting of fruit and vege-
table intake by disease status. Unfortunately, we have
no data to assess the direction and magnitude of the
potential bias. Because of the intrinsic limitations of
FFQ, the error in measuring micronutrient intake
could be substantial. Furthermore, the intake of
onions, which are rich sources of quercetin and
kaempferol, was not recorded in our study.
Nonparticipation and unwillingness of some parti-
cipants to provide food intake informationmay have led
to selection bias. For this bias to occur, the association
between flavonoid intake and selection would have to
differ for cases and controls, which seems unlikely.
Moreover, we observed similar distributions for age, sex,
educational level, and tobacco smoking between indivi-
duals with andwithout FFQ information.
Residual confounding might exist when evaluat-
ing the effects of various flavonoid compounds,
although we controlled for well-documented risk fac-
tors. Vegetables, fruits, tea, and wine may contain
unknown biologically active compounds, which may
be correlated with flavonoid compounds but were
not controlled for in the study. In addition, flavonoid
compounds are usually correlated with each other,
because they share common rich sources. The high
correlation between epicatechin, catechin, quercetin,
and kaempferol limited our ability to separate their
effects. Nonetheless, when we included epicatechin,
catechin, quercetin, and kaempferol as covariates
along with the risk factors that were controlled in
previous models, the inverse association with lung
cancer remained only for catechin.
The median age at diagnosis for lung cancer in
the United States is 70 years.36 Because our study
was restricted to individuals aged <65 years, study
cases were relatively young (median age, 52 years).
Therefore, our study results may not be generalizable
to older populations.
In conclusion, we observed inverse associations
of epicatechin, catechin, quercetin, and kaempferol
TABLE 4
Intakes of Vegetables, Fruits, Tea, and Wine in Association
With Lung Cancer Risk
Intake
OR (95% CL)
All study participants* Smokers* Nonsmokersy
Total vegetables (servings per day)
3{ 0.68 (0.51–0.90) 0.59 (0.42–0.83) 0.94 (0.56–1.6)
Ptrend .0079 .0026 .83
<1 1.0 1.0 1.0
1 to <2 0.98 (0.66–1.5) 0.84 (0.53–1.3) 2.0 (0.82–4.8)
2 to <3 0.80 (0.53–1.2) 0.69 (0.43–1.1) 1.6 (0.62–3.9)
3 0.56 (0.37–0.87) 0.49 (0.29–0.82) 1.0 (0.40–2.7)
Total fruits (servings per day)
3{ 1.1 (0.85–1.4) 1.0 (0.76–1.4) 1.1 (0.74–1.5)
Ptrend .57 .79 .75
<1 1.0 1.0 1.0
1 to <2 0.88 (0.63–1.2) 0.92 (0.62–1.4) 0.85 (0.41–1.7)
2 to <3 0.97 (0.67–1.4) 1.0 (0.64–1.6) 0.94 (0.44–2.0)
3 1.0 (0.71–1.5) 0.98 (0.62–1.6) 1.1 (0.51–2.3)
Tea (cups per day)
1{ 0.83 (0.69–1.0) 0.79 (0.63–0.98) 0.90 (0.63–1.3)
Ptrend .054 .033 .56
0 1.0 1.0 1.0
>0 to 1 0.64 (0.49–0.85) 0.61 (0.44–0.85) 0.83 (0.49–1.4)
>1 0.42 (0.24–0.73) 0.37 (0.19–0.72) 0.52 (0.18–1.5)
Wine (glasses per day in the past year)k
1{ 0.78 (0.61–0.98) 0.76 (0.59–0.97) 1.07 (0.43–2.69)
Ptrend .037 .029 .89
0 1.0 1.0 1.0
>0 to 1 0.68 (0.50–0.94) 0.50 (0.34–0.74) 1.27 (0.69–2.36)
>1 0.33 (0.15–0.75) 0.32 (0.14–0.74) —§
Wine (glasses per day, life-time average)k
1{ 0.94 (0.68–1.31) 0.96 (0.67–1.38) 0.88 (0.37–2.12)
Ptrend .73 .82 .78
0 1.0 1.0 1.0
>0 to 1 0.66 (0.48–0.90) 0.58 (0.40–0.83) 0.81 (0.41–1.59)
>1 1.27 (0.72–2.25) 1.21 (0.65–2.27) 1.35 (0.33–5.63)
OR indicates odds ratio; 95% CL, 95% confidence limits.
* Adjusted for age (in 14 fine categories), sex, race-ethnicity (non-Hispanic white, black, Hispanic,
other), years of schooling, smoking status (ever vs never), pack-years of tobacco smoking, and daily
energy intake.
y Adjusted for age (in 14 fine categories), sex, race-ethnicity (non-Hispanic white, black, Hispanic,
other), years of schooling, and daily energy intake.
{ Treating intakes of vegetable, fruit, tea, and wine as continuous variables with rescaling and exclu-
sion of outliers.
§ No estimation because of sparse data.
k Data on wine intake in the past year were collected by the food frequency questionnaire; life-time
average wine intake was recorded in the alcoholic beverage drinking history. Beer and liquor drinking
also was controlled in the model.
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intakes with lung cancer among tobacco smokers.
Although these observations are consistent with lab-
oratory findings, large randomized trials would be
needed to determine whether they indeed represent
preventive effects.
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